ERBB2 and gastric carcinoma: In literature there are congruent data about the rate of Her2 overexpressed and amplified tumors in gastric cancer but there are still inconsistent results regarding any prognostic value of Her2 in gastric carcinomas and adenocarcinomas of the gastroesophageal junction [2,3,7].